BTK and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, there are multikinase inhibitors, such as LFM-A13, which inhibits BTK and polo-like kinase (PLK), fostamatinib, which inhibits the δ isoform of PI3K and Syk [61], and dasatinib, initially developed as an inhibitor of tyrosine kinase for CML patients, which is also a BTK inhibitor.